Synergy Pharmaceuticals
6334 Winfield Boulevard
Margate
Florida
33063
United States
Tel: 954-801-3950
222 articles about Synergy Pharmaceuticals
-
Recent Discovery in the Cure for Herpes is Overshadowed by the Covid -19 Quest for a VaccineLack of coverage has left millions infected with herpes in the dark.
7/7/2020
The race is on to find a vaccine for COVID-19, the illness caused by the novel coronavirus.
-
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Synergy Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline - SGYP
4/10/2019
Pomerantz LLP announces that a class action lawsuit has been filed on behalf of investors in Synergy Pharmaceutical, Inc. against certain of the Company's current and former officers and directors.
-
Synergy Pharmaceuticals Announces Completion of Sale to Bausch Health
3/6/2019
All rights to TRULANCE® (plecanatide), dolcanatide and the related intellectual property have been transferred to Bausch Health.
-
Bausch Health Completes Acquisition Of Certain Assets Of Synergy Pharmaceuticals Inc.
3/6/2019
Synergy's flagship product, TRULANCE® is a once-daily tablet approved for adults with chronic idiopathic constipation and irritable bowel syndrome with constipation, and its investigational compound, dolcanatide, is an incremental peptide with established proof-of-concept studies in multiple GI conditions.
-
Synergy Pharmaceuticals Receives Court Approval for the Sale of Its Assets to Bausch Health
3/1/2019
Synergy Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal therapies, confirmed that the previously announced agreement with Bausch Health Companies Inc.
-
Synergy Pharmaceuticals Confirms Bausch Health as Successful Bidder for Its Business Assets
2/26/2019
Synergy Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal therapies, confirmed that the previously announced agreement with Bausch Health Companies Inc.
-
Bausch Health to Acquire Certain Assets of Synergy Pharmaceuticals Inc.
2/26/2019
Bausch Health and Synergy to Seek Bankruptcy Court Approval of Sale on March 1, 2019
-
Synergy Pharmaceuticals Announces Agreement for Bausch Health to Acquire Its Business Assets
12/12/2018
Company Initiates Voluntary Chapter 11 Process to Effectuate Sale; Secures Commitment for DIP Financing to Support Normal-Course Operations
-
Bausch Health Companies is acquiring basically all of Synergy Pharmaceuticals’ assets, including all rights to Trulance (plecanatide), dolcanatide and related intellectual property.
-
Synergy Pharmaceuticals Reports Third Quarter 2018 Financial Results and Business Update
11/8/2018
Synergy Pharmaceuticals Inc. today reported its financial results and business update for the three months ended September 30, 2018.
-
Synergy Pharmaceuticals Names Dr. Melvin K. Spigelman Chairman
10/31/2018
Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that Melvin K. Spigelman, M.D., who has served as an Independent Director of Synergy since August 2008, will now assume the role of Chairman of the Board, effective immediately.
-
After providing an update of its ongoing strategic review, New York-based Synergy Pharmaceuticals’ stock plunged more than 71 percent.
-
Synergy Pharmaceuticals Provides Business Update
10/25/2018
Synergy Pharmaceuticals Inc. today provided a business update.
-
Synergy Pharmaceuticals Presents New Analyses Supporting the Use of TRULANCE® (plecanatide) in Two Patient Populations at the American College of Gastroenterology (ACG) Annual Scientific Meeting
10/8/2018
New analyses results reinforce effectiveness and safety for the use of TRULANCE in adults with CIC or IBS-C
-
Synergy Pharmaceuticals to Present New Analyses of TRULANCE® (Plecanatide) at the American College of Gastroenterology (ACG) Annual Scientific Meeting
10/1/2018
New analyses further reinforce effectiveness and safety in important subpopulations of adults with CIC or IBS-C
-
Synergy Pharmaceuticals Strengthens Coverage for TRULANCE® (plecanatide) with Key New Market Access Wins
9/24/2018
Several new formulary wins improve TRULANCE 2018 and 2019 coverage status across major U.S. Commercial, Medicare Part D and Managed Medicaid plans.
-
CORRECTING and REPLACING Synergy Pharmaceuticals Reports Second Quarter 2018 Financial Results and Business Update
8/8/2018
CORRECTION...by Synergy Pharmaceuticals Inc.
-
Synergy Pharmaceuticals Reports Second Quarter 2018 Financial Results and Business Update
8/7/2018
TRULANCE® second quarter net sales up over 40% versus prior quarter
-
Synergy Pharmaceuticals Announces TRULANCE® (plecanatide) Added to Express Scripts 2019 National Preferred Formulary List
8/7/2018
Synergy Pharmaceuticals Inc. announced that leading U.S. pharmacy benefit manager, Express Scripts, will add TRULANCE to its National Preferred Formulary List, effective January 1, 2019.
-
Synergy Pharmaceuticals Announces License Agreement with Luoxin Pharmaceutical Group for TRULANCE® (plecanatide) in China
8/7/2018
Synergy Pharmaceuticals Inc. announced that the company has entered into a license agreement with Luoxin Pharmaceutical Group Co., Ltd., Shandong (Luoxin) providing Luoxin exclusive rights to develop and commercialize Synergy’s lead product TRULANCE® (plecanatide)